Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer-Reference-Cited by-同舟云学术

Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer

Published:2021-05 Issue:14 Volume:17 Page:1749-1759
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Barone Carlo¹^ORCID,Bartolomeo Maria Di²,Lonardi Sara³,Maiello Evaristo⁴,Martinelli Erika⁵,Moretto Roberto⁶,Strippoli Antonia¹,Tamburini Emiliano⁷,Zaniboni Alberto⁸,Pinto Carmine⁹

Affiliation:

1. Oncologia Medica, Fondazione Policlinico A. Gemelli-IRCCS, Università Cattolica del S. Cuore, Rome, Italy

2. Oncologia Medica, Istituto Nazionale dei Tumori-IRCCS, Milan, Italy

3. Oncologia Medica, Istituto Oncologico Veneto-IRCCS, Padua, Italy

4. Dipartimento di Onco-Ematologia, Casa Sollievo della Sofferenza Hospital, S. Giovanni Rotondo, Foggia, Italy

5. Dipartimento di Internistica Clinica e Sperimentale, Università della Campania “Luigi Vanvitelli”, Naples, Italy

6. Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie, University of Pisa, Pisa, Italy

7. Dipartimento di Oncologia Medica, Ospedale Cardinale G. Panico, Tricase, Lecce, Italy

8. Oncologia Medica, Fondazione Poliambulanza, Brescia, Italy

9. Oncologia Medica, Clinical Cancer Center, AUSL-IRCCS, Reggio Emilia, Italy

Abstract

Aim: To help to remove misperception of an appropriate position of trifluridine/tipiracil (FTD/TPI) in the treatment of metastatic colorectal cancer. Materials & methods: The RAND Corporation/UCLA Appropriateness Method was used by a panel of Italian experts to develop recommendations concerning daily practice with FTD/TPI. Forty-three clinical scenarios were discussed in two rounds and the resulting statements were rated as appropriate, uncertain or inappropriate, according to the median score. Results: Several topics were dealt with, covering the profile of eligible patients, therapeutic options beyond the second line, the practice of treatment with FTD/TPI, evaluation and efficacy and toxicity, as well as costs and compliance. Conclusion: FTD/TPI is an important therapeutic resource in refractory metastatic colorectal cancer that combines manageability and safety.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-1181

Reference38 articles.

1. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides

2. Trifluridine to enhance cytotoxicity by DNA mismatch repair deficiency and subsequent MBD4 frameshift mutation in colorectal cancer.

3. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors